Compare Solaris Energy Infrastructure Inc. Class A Common Stock (SEI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solaris Energy Infrastructure Inc. Class A Common Stock vs Viatris Inc — how do they compare? Solaris Energy Infrastructure Inc. Class A Common Stock trades at $68.5 (market cap $5.12B), while Viatris Inc trades at $17.58 (market cap $19.81B). The key difference: Viatris Inc is far larger — about 3.9× Solaris Energy Infrastructure Inc. Class A Common Stock's market cap, and Viatris Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals — on Pluang, investors hold Solaris Energy Infrastructure Inc. Class A Common Stock for 0 Days and Viatris Inc for 57 Days on average.
| SEI | VTRS | |
|---|---|---|
Market Cap | $5.12B | $19.81B |
Volume | 2,532,496 | 7,547,542 |
Sector | Energy | Health |
52-Week High | $82.88 | $18.27 |
52-Week Low | $40.64 | $9.98 |
Typical Hold Time | 0 Days | 57 Days |
Enterprise Value | $6.81B | $31.92B |
Dividend Yield | 0.62% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SEI (Solaris Energy Infrastructure) trades at $77.83, down 1.83% today, but maintains strong analyst support with 9 unanimous buy ratings and a $100.56 consensus price target. The stock shows positive momentum with three consecutive quarterly earnings beats and projected revenue growth from $622M in 2025 to $762M in 2026. Recent technical analysis indicates neutral signals with support at $76 and resistance at $79.
The outlook remains positive given strong earnings performance and expansion initiatives, though elevated valuation ratios (P/E of 98.52) and significant debt issuance ($1.25B notes) present risks. The upcoming Q3 2026 earnings report on October 21 will be crucial for validating growth trajectory amid energy sector volatility.
Viatris (VTRS) trades at $17.44, down 0.57% on the day, with a bullish technical signal supported by moving averages. The company has beaten earnings estimates for three consecutive quarters, though it reported a net loss of $3.51B in 2025. Recent news highlights include FDA approval for WAKIX in Japan and recognition as a top employer. Analyst consensus is mixed with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but faces fundamental challenges including negative profit margins and high debt. Positive cash flow generation and consistent earnings beats provide support, while competitive pressures and execution risks remain concerns for investors seeking turnaround potential in the healthcare sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Solaris Energy Infrastructure Inc. Class A Common Stock
Solaris Energy Infrastructure, Inc. provides mobile power generation, control, and distribution equipment and logistics equipment for managing raw materials at well sites, operating through its Solaris Power Solutions and Solaris Logistics Solutions segments for data center, energy, commercial, and industrial customers.
Read more on SEI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
